Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
DUBLIN, Ireland, March 01, 2016 -- SIGMOID PHARMA LIMITED, a privately-owned, specialty pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases using its proprietary SmPill® solid oral delivery system, announced today that Dr. Ivan Coulter, Chief Executive Officer, will provide a corporate update at the 36th Annual Cowen & Co. Healthcare Conference, taking place in Boston, Massachusetts March 7-9, 2016.
| Presentation Details: | |
| Title: | 36th Annual Cowen & Company Healthcare Conference |
| Date: | March 9th |
| Time: | 10:30am Eastern Time |
| Location: | MIT Room, The Marriott Copley Hotel, Boston. |
About Sigmoid Pharma
Sigmoid Pharma is a specialty pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases. The Company’s Single-Multiple Pill (SmPill®) technology is a versatile delivery system for optimising the formulation of active therapeutic agents and allowing targeted release at the site of disease. Sigmoid’s lead program is CyCol®, a colon-targeted, formulation of cyclosporine that permits local, topical exposure of a powerful immunosuppressant whilst minimizing systemic blood levels, thus offering the potential for an efficacious and safe oral treatment of moderate-severe ulcerative colitis (UC). Another pipeline product is has received US FDA Orphan Designation for Graft-versus-Host Disease. For additional information please visit: http://www.sigmoidpharma.com
For further information contact: Leo Toole Chief Financial Officer Sigmoid Pharma Ltd, Blocks 9/10 Nexus UCD, Belfield Office Park, Beech Hill Road, Dublin 4, D04 V2N9, Ireland. Phone +353 (0) 1 700 7452 E-mail: [email protected] US Investors: Andrew McDonald Ph.D. LifeSci Advisors LLC [email protected]
